<DOC>
	<DOCNO>NCT00107094</DOCNO>
	<brief_summary>In trial , safety combination treatment Adriamycin plus cyclophosphamide follow Abraxane adjuvant therapy evaluate patient limited stage breast cancer .</brief_summary>
	<brief_title>Study Adriamycin Plus Cyclophosphamide Followed Abraxane Adjuvant Therapy Patients With Breast Cancer</brief_title>
	<detailed_description>This open-label , pilot study evaluate safety Adriamycin cyclophosphamide ( AC ) administer every 2 week 4 cycle follow Abraxane administer every 2 week 4 cycle adjuvant therapy patient limited stage breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>A patient eligible inclusion study follow criterion meet : Estrogen Receptor ( ER ) Progesterone Receptor ( PR ) status determine Operable , histologically confirm adenocarcinoma breast Must meet 1 follow criterion : T13 , N12 , M0 , regardless ER PR status ; T &gt; 2 cm , N0 , M0 , regardless ER PR status ; T &gt; 1 cm , N0 , M0 ER PR negative ; T12 1 sentinel node micrometastasis &lt; 2 mm without axillary dissection , M0 ; T12 &gt; 1 sentinel node micrometastasis 1 node macrometastasis &gt; 2 mm and/or T3 must axillary dissection , M0 . Negative surgical margin lumpectomy mastectomy specimen ( ink invasive cancer ink DCIS [ ductal carcinoma situ ] ) . ECOG performance status 01 Adequate wound healing , determine treat physician It longer 84 day since date definitive surgery ( e.g. , mastectomy , case breastsparing procedure , axillary dissection ) . Previous invasive cancer treat &gt; 5 year prior enter study , except basal squamous cell carcinoma skin carcinoma situ cervix , latter require occur 5 year prior study entry . Prior invasive breast cancer diagnose &gt; 5 year prior enter study . Patients must finish adjuvant hormonal therapy prior registration . Patients prior DCIS eligible . Patients DCIS treat tamoxifen must finish tamoxifen prior registration . Laboratory value must follow : White blood cell count : ≥3,000/mm3 ; Absolute neutrophil count : ≥1,500/mm3 ; Platelets : ≥100,000/mm3 ; Hemoglobin : ≥8 g/dL ; Bilirubin : ≤ institution ’ ULN ( upper limit normal ) ; Creatinine : ≤1.5 mg/dL ; Calculated creatinine clearance &gt; 30 mL/min ; AST ALT alkaline phosphatase may 2.5 × institutional ULN . All stag study include physical exam , chest xray , bone scan must show evidence metastatic disease , include suspicious lymphadenopathy skin nodule physical exam . A chest xray bone scan mandatory ; however , stag study treat physician ’ discretion . Any staging test ( e.g. , CT scan , MRI study , ultrasound abdomen , PET scan ) must negative metastatic disease . An abdominal CT scan PET scan mandatory patient liver function test elevate ULN rule metastatic disease . Patient negative serum pregnancy test within 10 day prior registration ( patient childbearing potential ) . If fertile , patient agree use acceptable method birth control avoid pregnancy [ Note : oral contraceptive allow ] duration study . Patient sign Patient Informed Consent Form A patient eligible inclusion study follow criterion apply : Any evidence disease follow surgical resection primary tumor include : positive surgical margin , stag workup , physical examination suspicious malignant disease . Stage IIIb breast cancer ( T4 disease , i.e. , patient fix tumor , peau d'orange skin change , skin ulceration , inflammatory change ) . Stage IV breast cancer . Prior anthracycline , anthracenedione ( mitoxantrone ) , taxane therapy . Neoadjuvant therapy breast cancer . Peripheral neuropathy &gt; Grade 1 . Serious medical illness , treat study , would limit survival &lt; 2 year , psychiatric condition would prevent informed consent . Uncontrolled severe cardiovascular disease include recent ( &lt; 6 month ) myocardial infarction , congestive heart failure . Active uncontrolled bacterial , viral ( include clinically define AIDS ) , fungal infection . Patients active hepatitis abnormal LFTs ( liver function test ) patient know HIV positive Uncontrolled disease uncontrolled diabetes Obese patient Investigator comfortable administer full dos study drug calculate BSA ( body surface area ) . Patients receive concurrent immunotherapy . A history malignancy within last 5 year , could affect diagnosis assessment highrisk breast cancer . Patient organ allograft . Patient pregnant breastfeeding . Patient unable comply study requirement . Patient receive investigational drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Abraxane</keyword>
</DOC>